Head to Head Survey: Precision Therapeutics (NASDAQ:POAI) vs. MSA Safety (NASDAQ:MSA)

Share on StockTwits

Precision Therapeutics (NASDAQ:POAI) and MSA Safety (NYSE:MSA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Volatility and Risk

Precision Therapeutics has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, MSA Safety has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Insider & Institutional Ownership

1.1% of Precision Therapeutics shares are held by institutional investors. Comparatively, 75.3% of MSA Safety shares are held by institutional investors. 13.4% of Precision Therapeutics shares are held by insiders. Comparatively, 9.1% of MSA Safety shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.


This table compares Precision Therapeutics and MSA Safety’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Precision Therapeutics -925.08% -714.98% -255.28%
MSA Safety 8.89% 28.35% 11.26%

Valuation and Earnings

This table compares Precision Therapeutics and MSA Safety’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Precision Therapeutics $1.41 million 12.40 -$10.09 million N/A N/A
MSA Safety $1.36 billion 2.84 $124.15 million $4.50 22.14

MSA Safety has higher revenue and earnings than Precision Therapeutics.


MSA Safety pays an annual dividend of $1.68 per share and has a dividend yield of 1.7%. Precision Therapeutics does not pay a dividend. MSA Safety pays out 37.3% of its earnings in the form of a dividend. MSA Safety has increased its dividend for 47 consecutive years.

Analyst Ratings

This is a summary of recent recommendations and price targets for Precision Therapeutics and MSA Safety, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Precision Therapeutics 0 0 0 0 N/A
MSA Safety 0 2 1 0 2.33

MSA Safety has a consensus target price of $106.10, suggesting a potential upside of 6.49%. Given MSA Safety’s higher probable upside, analysts plainly believe MSA Safety is more favorable than Precision Therapeutics.


MSA Safety beats Precision Therapeutics on 10 of the 14 factors compared between the two stocks.

Precision Therapeutics Company Profile

Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.

MSA Safety Company Profile

MSA Safety Incorporated develops, manufactures, and supplies safety products that protect people and facility infrastructures in the oil, gas, petrochemical, fire service, construction, utilities, and mining industries worldwide. It operates through Americas and International segments. The company's core product offerings include permanently installed fixed gas and flame detection instruments, such as permanently installed gas detection monitoring systems, and flame detectors and open-path infrared gas detectors, as well as replacement components and related services to detect the presence or absence of various gases in the air. Its core product offerings also consist of breathing apparatus products, such as self-contained breathing apparatus, face masks, and respirators; hand-held portable gas detection instruments; industrial head protection products; firefighter helmets and protective apparel; and fall protection equipment comprising confined space equipment, harnesses, lanyards, and lifelines. In addition, the company offers respirators, eye and face protection products, ballistic helmets, and gas masks. It serves distributors, and industrial or military end-users through indirect and direct sales channels. The company was founded in 1914 and is based in Cranberry Township, Pennsylvania.

Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.